In the latest of a series of articles for Slate.com, Bjorn Lomborg cites research from R4D experts arguing that an HIV vaccine should be the top priority for global philanthropists and policymakers.

“No disease comes close to the AIDS epidemic in threatening every aspect of development for dozens of countries,” Lomborg says, before citing research from R4D expert Dean Jamison, Managing Director Robert Hecht, Program Officer Kira Thorien, and Senior Program Associate Gabrielle Partridge, “that there is a strong case for increasing HIV vaccine research and development by $100 million annually. Even with conservative assumptions, each dollar spent would generate benefits worth 20 times the costs.”

Read the full article here.